AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03279289
Drug: 5Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg/m2 intravenous bolus
Trial: NCT02299661
Drug: DS-1093a
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-1093a, single oral doses up to 50 mg
Trial: NCT01964391
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin will be administered in combination with trastuzumab and cyclophosphamide in the adjuvant setting as per local Product Information and the investigator's discretion.
Trial: NCT01964391
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be administered in combination with trastuzumab and doxorubicin in the adjuvant setting as per local Product Information and the investigator's discretion.
Trial: NCT03104816
Drug: Acetaminophen IV Soln 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03104816
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04643600
Drug: L-Arginine, 500 Mg Oral Capsule
RxNorm normalized name: L-Arginine, 500 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The strength test of the the quadriceps muscle, will be measured in all patients on the Biodex isokinetic device. Quadriceps strength testing will be performed on 2 occasions. On one occasion without medication, except those that the patient may take permanently, and on the other 90 minutes after the patient takes 1 tbl of L - Arginine 500 mg on mouth to an empty stomach ,in order to monitor the possible increase in quadriceps strength.
Trial: NCT00334178
Drug: Laxymig ER (drug)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04064359
Drug: OBT076, a CD205-directed antibody-drug conjugate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) infusion of OBT076 every 3 weeks.
Trial: NCT01527786
Drug: Desvenlafaxine
RxNorm normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50mg-100mg everyday for 12 weeks over 7 study visits
Trial: NCT00204438
Drug: 0.15mg desogestrel /0.03mg ethinyl estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01904773
Drug: AZD5213 and placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: low dose AZD5213 capsules; high dose AZD5213 capsules; placebo capsules
Trial: NCT02876250
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a control group with IV administration of 2.5 mg/kg of placebo prior to first graft reperfusion
Trial: NCT03626298
Drug: Nicotinamide, ABA and Zinc PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination of three non-antibiotic active ingredients of nicotinamide, anti-bacterial adhesive agent (ABA) and zinc, or abbreviated as ANAZ to be well-tolerated by patients with acne vulgaris
Trial: NCT03985293
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 matching placebo tablets taken twice a day (BID)
Trial: NCT03626298
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream. to resemble an active medication or therapy so that it functions as a control; this is to prevent the recipient(s) and/or others from knowing (with their consent) whether a treatment is active or inactive, as expectations about efficacy can influence results.
Trial: NCT00791076
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2pmol/kg-1/min-1 placebo infused continuously over 72 hours.
Trial: NCT02718599
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive 50 ml normal saline at a rate of 100 ml/h followed by a continuous infusion of 50 ml at a rate equal to wt/10 ml per hour and weaned in the postoperative period over 4 hours.
Trial: NCT01873417
Drug: BG00012 (DMF)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00458016
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral administration
Trial: NCT01106469
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT02183701
Drug: Losartan + Hydrochlorothiazide
RxNorm normalized name: hydrochlorothiazide / losartan
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02183701
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02361476
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection - during surgery
Trial: NCT04565327
Drug: Hyperpolarized Carbon C 13 Pyruvate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV prior to imaging
Trial: NCT00814333
Drug: Merocel pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 cm pack, inserted within the affected side between the septum and inferior turbinate via bayonet forceps
Trial: NCT00830791
Drug: MK-0941 20 mg
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 10-mg tablets of MK-0941 administered as a single oral dose.
Trial: NCT00830791
Drug: MK-0941 5 mg
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0941 administered as one single 5-mg tablet.
Trial: NCT00010062
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00711165
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 puffs, qd
Trial: NCT03010475
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral administration. A total of three single doses.
Trial: NCT03010475
Drug: SNAC
RxNorm normalized name: Glucerna Snack Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration. A total of five single doses.
Trial: NCT04450316
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tab nightly
Trial: NCT01396499
Drug: BKM120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose 80 mg tablets by mouth daily for a 28 day cycle.
Trial: NCT04950660
Drug: Caffeine Tablet
RxNorm normalized name: Caffeine Tablets
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine is approved by the FDA as a stimulant. A stimulant approved by the United States Food and Drug Administration (FDA) for the treatment to increase mental alertness and in combination with painkiller to treat migraine headaches. It is approved in the form of pill or tablet.
Trial: NCT04950660
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, empty opaque dark blue blank capsule, taken twice daily. This will be an adjuvant to their standard pain control.
Trial: NCT04470726
Drug: AIV001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal/intratumoral
Trial: NCT04470726
Drug: AIV001 suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AIV001 is administered as a aqueous suspension by an intradermal/intratumoral injection
Trial: NCT03427788
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo, once daily in an escalating manner as LSF or tablets
Trial: NCT02111798
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be randomly assigned to receive placebo powder in twice-daily capsules at the end of week 2.
Trial: NCT03341741
Drug: Tobramycin Powder
RxNorm normalized name: tobramycin Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TOBI®Podhaler 2 x 112 mg daily for 2 x 28 days (on/off);
Trial: NCT01564056
Drug: HORMONOTHERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormonotherapy will be administered during 5 years following chemotherapy when allocated.~(Tamoxifen, aromatase inhibitor or sequential hormonotherapy) is left to the investigator judgement in both groups (I and II).
Trial: NCT00130312
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 placebo gelcap in the morning and evening
Trial: NCT03363022
Drug: Standard Medical Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Medical Treatment includes antibiotics,CRRT (Continuous Renal replacement Therapy),Liver Dialysis.
Trial: NCT05512468
Drug: carbon dye
RxNorm normalized name: amaranth dye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tattooing (marking) of biopsied node with carbon dye at the time or at a separate session of fine needle aspiration or core biopsy or separate visit under ultrasound guidance. The dye will be injected in the cortex of the node and the perinodal tissue under ultrasound guidance. Patients will undergo standard (routine) armpit surgery and may receive neoadjuvant chemotherapy as planned by the clinical team. This could be removal of a few lymph glands (sentinel node biopsy) or removal of all the lymph glands (axillary lymph node dissection) in the armpit. The surgeon will try to identify and remove the tattooed lymph gland at the time of planned armpit surgery.
Trial: NCT03273257
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be given analogue to riociguat with matching tablets.
Trial: NCT00864019
Drug: Zoloft® 100 mg tablets, single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B: Active comparator Subjects received Pfizer formulated products under non-fasting conditions
Trial: NCT01600222
Drug: LEO 90100
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate)
Trial: NCT03159897
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparator arm: cycle 1-2 (and eventually 3-6): 25 mg/m2 i.v. days 1,15. Experimental arm: Cycles 1 to 4: 35 mg/m2 i.v. days 1,11. Cycles 5 and 6: 25 mg/m2 i.v. days 1,11.
Trial: NCT00507728
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo by mouth for 12 weeks.
Trial: NCT00564486
Drug: IV Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV, every 6 hours for 24 hours (4 doses total)
Trial: NCT00564486
Drug: IV Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV, every 4 hours for 24 hours (6 doses total)
Trial: NCT00564486
Drug: IV Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV, every 6 hours for 24 hours (4 doses total)
Trial: NCT00564486
Drug: IV Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV, every 4 hours for 24 hours (6 doses total)
Trial: NCT02341573
Drug: experienced chinese herbal formulas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At the acute stage of asthma :Shegan mixture ; At the remission stage:Huangqi Bushen mixture; 10-30 mL , 2 times a day, for 3 months.
Trial: NCT00003472
Drug: Antineoplaston therapy (Atengenal + Astugenal)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adults with a recurrent/progressive Oligodendroglioma will receive Antineoplaston therapy (Atengenal + Astugenal).
Trial: NCT03126682
Drug: Wellbutrin SR 300Mg Extended-Release Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wellbutrin SR 300Mg Extended-Release Tablet
Trial: NCT02504060
Drug: Starch Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03918980
Drug: LOU064
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LOU064 will be administered as oral capsules in parts 1 to 6.
Trial: NCT03918980
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules will be administered in parts 1,2, 4 and 6.
Trial: NCT01935557
Drug: Continuous heparin infusion
RxNorm normalized name: Uniphyllin Continus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: continuous group is given an initial intravenous heparin 100u/kg and then maintain heparin infusion during procedural.
Trial: NCT01935557
Drug: Intermittent heparin infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent group is given an initial intravenous heparin 100u/kg. Then The ACT is tested every 30min with administration of additional heparin boluses and titration of the heparin drip based on the results and according to the judgment of the operating physician.
Trial: NCT00798707
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets (25 or 50 mg). Daily dosing for 10 +/- 4 days during a placebo lead-in period, and then 8 weeks during the double-blind period.
Trial: NCT03256526
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg
Trial: NCT04177173
Drug: Simvastatin 20 mg
RxNorm normalized name: simvastatin 20 MG
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: improvement of disease activity
Trial: NCT04177173
Drug: Methotrexate 10 mg
RxNorm normalized name: methotrexate 10 MG
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: improvement of disease activity
Trial: NCT00864604
Drug: Nabumetone 750 mg tablets, single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A: Experimental Subjects received Actavis Elizabeth LLC formulated products under fed conditions
Trial: NCT00864604
Drug: Nabumetone 750 mg tablets, single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B: Active comparator Subjects received Teva formulated products under fed conditions
Trial: NCT02875340
Drug: VAL401
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone formulated into a liquid lipid filled capsule
Trial: NCT03467152
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hypromellose capsules.
Trial: NCT04844710
Drug: standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard care only
Trial: NCT02437227
Drug: CCT3833
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCT3833 is a poorly soluble crystalline compound. It is multi-polymorphic and one form, designated Form D, has been purified and typically has a particle size of about 15-20 μm. Form D readily absorbs and desorbs water, but is not a hydrate and has been selected as the form to take forward into clinical development.
Trial: NCT02639026
Drug: MEDI4736
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/kg MEDI4736 every 4 weeks for 4 doses, followed by 10 mg/kg MEDI4736 monotherapy every 2 weeks for 18 doses
Trial: NCT01506986
Drug: Lansoprazole 30mg, Clarithromycin 500mg, Metronidazole 400mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All three medications will be taken orally, twice daily, for seven days.
Trial: NCT01506986
Drug: Placebo lansoprazole 30mg, clarithromycin 500mg, metronidazole 400mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication to be taken orally, twice a day, for seven days.
Trial: NCT02933229
Drug: H. pylori eradication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H. pylori eradication therapy comprising esomeprazole, amoxicillin,clarithromycin and colloidal bismuth pectin.~If failed in eradicating H. pylori, a culture based antimicrobial susceptibility test will be used to guide H. pylori eradication.
Trial: NCT00318942
Drug: Crystalloids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic or hypertonic saline or Ringer Lactate or any other crystalloids, at the necessary dose to restore hemodynamic for all ICU stay
Trial: NCT00318942
Drug: Colloids
RxNorm normalized name: Technetium (99mTc), particles and colloids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelatines, Albumine, Starch, or any other colloids, at the necessary dose to restore hemodynamic (starch cumulative daily dose should not exceed 35/40 ml/kg), for all ICU stay
Trial: NCT00318942
Drug: Crystalloids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any crystalloids given for correction of hypovolemia during all ICU stay
Trial: NCT00318942
Drug: Colloids
RxNorm normalized name: Technetium (99mTc), particles and colloids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any colloids given for correction of hypovolemia during all ICU stay
Trial: NCT02880085
Drug: Local anesthetic
RxNorm normalized name: Local anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: local injection
Trial: NCT00996008
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g (w/w) placebo cream applied to each target lesion twice daily
Trial: NCT00034359
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03993288
Drug: Ferrum Lek® (iron (III) hydroxide polymaltosate), 100 mg chewable tablets (Lek d.d., Slovenia)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received Ferrum Lek® 2 tablets daily (200 mg) for 12 weeks
Trial: NCT00583128
Drug: AST-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, sachet, 2 grams three times daily for 8 weeks
Trial: NCT00583128
Drug: Celphere® CP-305
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, placebo, sachet, 2 grams three times daily for 8 weeks
Trial: NCT02729545
Drug: Cyproterone acetate/ethinylestradiol (CPA/EE)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproterone acetate/ethinylestradiol (CPA/EE) contains 2mg cyproterone acetate (an anti-androgenic progestin) and 0.035mg ethinylestradiol (CPA/EE). The pills were administered for 21 days consecutively. The patients then stopped taking the pills for seven days and, on the eighth day, continued to take the pills again for three menstrual cycles (28 day cycles).
Trial: NCT01889381
Drug: Bone marrow cell-based therapy & 1-drug immunosuppression.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This protocol uses a novel bone marrow cell-based therapy for composite tissue allotransplantation (CTA) rather than conventional triple-drug immunosuppression to facilitate long-term graft survival of deceased donor human faces under low-dose maintenance immunosuppression. Initial T-cell depletion with alemtuzumab is followed by upper extremity transplantation and tacrolimus maintenance therapy. Donor bone marrow cells are infused on Day 10 (±4 days) post-transplantation to elicit a host alloimmune response triggering exhaustion and deletion of the respective host (anti-donor) lymphocyte clones. Subsequently, tacrolimus therapy is given for at least 6 months before spaced weaning is considered in stable recipients.
Trial: NCT04371874
Drug: Hydrochlorothiazide, Captopril, Nitrendipine, Aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants were grouped into a control group and a TDP group. Hypertension of patients in the control group was managed with the original protocol by doctors in village clinics. Patients in the TDP group were supplied with the TDP treatment, for whom different levels of oral administration plans to patients without drugs treatment in original protocol were: G 0 and G I, nifedipine (20mg, bid) or captopril (25mg, tid), hydrochlorothiazide (12.5mg, bid) for patients who couldn't tolerate previous drugs; G II, nifedipine (20mg, bid) plus hydrochlorothiazide (12.5mg, bid), or captopril (25mg, tid) plus hydrochlorothiazide (12.5mg, bid ), triple therapy for patients whose blood pressure did not reach target BP; G III, three drugs combination. Patients with drugs treatments in the original protocol were changed to be treated with the above antihypertension medications which were uniformly supplied by the government.
Trial: NCT01389700
Drug: SAR279356
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous infusion
Trial: NCT01389700
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous infusion
Trial: NCT04038255
Drug: Nicoderm C-Q Transdermal Product
RxNorm normalized name: Nicoderm C-Q Transdermal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 weeks of nicotine replacement therapy patches
Trial: NCT03978143
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 250 mg crizotinib dose as coated microsphere 1 (cMS1) formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.
Trial: NCT03978143
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single 250 mg crizotinib dose as coated microsphere 2 (cMS2) formulation will be administered on the morning of Day 1 after overnight fast of at least 10 hours.
Trial: NCT03978143
Drug: Treatment G
RxNorm normalized name: VanaLice Lice Killing Treatment Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg esomeprazole will be administered~1 hour prior to dinner on Day -5 through Day -1. A single 250 mg crizotinib dose as cMS1 formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.
Trial: NCT03978143
Drug: Treatment H
RxNorm normalized name: Walgreens Lice Treatment Homeopathic Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg esomeprazole will be administered~1 hour prior to dinner on Day -5 through Day -1. A single 250 mg crizotinib dose as cMS2 formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.
Trial: NCT00732901
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily days 1-28
Trial: NCT05905614
Drug: SPH4336 Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label SPH4336 Tablets ：Administered by oral
Trial: NCT00853268
Drug: OxyContin® 40 mg tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OxyContin® 40 mg tablet, single dose with food
Trial: NCT04305184
Drug: ASP0598
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASP0598 Otic solution was administered onto the Tympanic Membrane (TM) through the external auditory canal via syringe.